Oppenheimer initiated coverage on Entrada Therapeutics with a new price target

1/5/24 8:45:46 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Oppenheimer initiated coverage of Entrada Therapeutics with a rating of Outperform and set a new price target of $22.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TRDA

Date	Price Target	Rating	Analyst
12/6/2024	$29.00	Buy	ROTH MKM
1/5/2024	$22.00	Outperform	Oppenheimer
4/3/2023	$25.00	Buy	H.C. Wainwright
11/24/2021		Outperform	Evercore ISI Group
11/23/2021		Outperform	Cowen & Co.
11/23/2021	$29.00	Neutral	Goldman Sachs